TP53 and lymphoma: NCT05631886 is a parallel pilot trial evaluating an EphA2‐directed CAR‐DC vaccine loaded with a TP53 mutant peptide (TP53‐EphA2‐CAR‐DCs) plus ICIs in solid tumours or R/R lymphomas.